{"pmid":32296777,"pmcid":"PMC7147223","title":"Mesenchymal stem cells and management of COVID-19 pneumonia.","text":["Mesenchymal stem cells and management of COVID-19 pneumonia.","Human coronavirus, hCoV-19, is highly pathogenic with severe pneumonia associated with rapid virus replication. Arising in Wuhan China December 2019, the current COVID-19 epidemic has rapidly grown with person-to-person infection expanding to become a global health emergency now on pandemic scale. Governments will not be able to minimise both deaths from COVID-19 and the economic impact of viral spread in mitigation of this current COVID-19 pandemic, according to Anderson et al. 2020 [1], Keeping mortality as low as possible will be the highest priority for individuals; hence governments must put in place measures to ameliorate the inevitable economic downturn. The current global picture shows small chains of transmission in many countries and large chains resulting in extensive spread in a few countries, such as Italy, Iran, South Korea, and Japan. Most countries are likely to have spread of COVID-19, at least in the early stages, before any mitigation measures have an impact. The scale of the problem is massive. Here I consider new approaches to improve patient's biological resistance to COVID-19 using stem cells, and how benefit might be scaled and simplified using synthetic stem cells to meet logistical needs within a short time frame.","Med Drug Discov","Metcalfe, Su M","32296777"],"abstract":["Human coronavirus, hCoV-19, is highly pathogenic with severe pneumonia associated with rapid virus replication. Arising in Wuhan China December 2019, the current COVID-19 epidemic has rapidly grown with person-to-person infection expanding to become a global health emergency now on pandemic scale. Governments will not be able to minimise both deaths from COVID-19 and the economic impact of viral spread in mitigation of this current COVID-19 pandemic, according to Anderson et al. 2020 [1], Keeping mortality as low as possible will be the highest priority for individuals; hence governments must put in place measures to ameliorate the inevitable economic downturn. The current global picture shows small chains of transmission in many countries and large chains resulting in extensive spread in a few countries, such as Italy, Iran, South Korea, and Japan. Most countries are likely to have spread of COVID-19, at least in the early stages, before any mitigation measures have an impact. The scale of the problem is massive. Here I consider new approaches to improve patient's biological resistance to COVID-19 using stem cells, and how benefit might be scaled and simplified using synthetic stem cells to meet logistical needs within a short time frame."],"journal":"Med Drug Discov","authors":["Metcalfe, Su M"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32296777","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.medidd.2020.100019","keywords":["Corona virus","Cytokine storm","Leukaemia inhibitory factor","Mesenchymal stem cells","Synthetic stem cells"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Wuhan","China","Italy","Iran","South Korea","Japan"],"countries":["Italy","Korea, Republic of","Japan","China","Iran, Islamic Republic of"],"countries_codes":["ITA|Italy","KOR|Korea, Republic of","JPN|Japan","CHN|China","IRN|Iran, Islamic Republic of"],"_version_":1664266651169718272,"score":8.233237,"similar":[{"pmid":32283904,"title":"The Early Impact of the Covid-19 Pandemic on the Global and Turkish Economy.","text":["The Early Impact of the Covid-19 Pandemic on the Global and Turkish Economy.","BACKGROUND/AIM: Individuals infected by the Covid-19 potentially are at risk of health and economic well-being. Today, the Covid-19 is a global issue, and the world economy can be interpreted as almost at the standstill. In this context, this study aims to discuss the potential first reactions of short and long term global economic impacts of the pandemic through sectors by assessing its costs according to the data announced for both the world and Turkey. In addition, this study tries to put forth possible economic and political scenarios for the post-pandemic world. MATERIALS AND METHODS: This is a review article that summarizes the current reports and discussions about the economic consequences of this historical event, and tries to make some inferences considering them. RESULTS: This pandemic has severe adverse effects on the employees, customers, supply chains and financial markets, in brief, most probably it will cause a global economic recession. Nevertheless, due to the uncertainty of the end of this pandemic, both the length and scale of this contraction are not predictable. CONCLUSION: It takes a while for the world economy to recover from the contraction. It seems that this pandemic will lead to a permanent shift in the world and its politics, especially in health, security, trade, employment, agriculture, manufacturing goods production and science policies. Since this new world might provide great opportunities for some countries that did not dominate world production before, governments should develop new strategies to adjust the new world order without much delay.","Turk J Med Sci","Acikgoz, Omer","Gunay, Asli","32283904"],"abstract":["BACKGROUND/AIM: Individuals infected by the Covid-19 potentially are at risk of health and economic well-being. Today, the Covid-19 is a global issue, and the world economy can be interpreted as almost at the standstill. In this context, this study aims to discuss the potential first reactions of short and long term global economic impacts of the pandemic through sectors by assessing its costs according to the data announced for both the world and Turkey. In addition, this study tries to put forth possible economic and political scenarios for the post-pandemic world. MATERIALS AND METHODS: This is a review article that summarizes the current reports and discussions about the economic consequences of this historical event, and tries to make some inferences considering them. RESULTS: This pandemic has severe adverse effects on the employees, customers, supply chains and financial markets, in brief, most probably it will cause a global economic recession. Nevertheless, due to the uncertainty of the end of this pandemic, both the length and scale of this contraction are not predictable. CONCLUSION: It takes a while for the world economy to recover from the contraction. It seems that this pandemic will lead to a permanent shift in the world and its politics, especially in health, security, trade, employment, agriculture, manufacturing goods production and science policies. Since this new world might provide great opportunities for some countries that did not dominate world production before, governments should develop new strategies to adjust the new world order without much delay."],"journal":"Turk J Med Sci","authors":["Acikgoz, Omer","Gunay, Asli"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32283904","week":"202016|Apr 13 - Apr 19","doi":"10.3906/sag-2004-6","keywords":["Covid-19; economy; pandemic"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Turkey"],"countries":["Turkey"],"countries_codes":["TUR|Turkey"],"_version_":1664071627227267072,"score":236.75122},{"pmid":32296266,"pmcid":"PMC7158845","title":"Initial impacts of global risk mitigation measures taken during the combatting of the COVID-19 pandemic.","text":["Initial impacts of global risk mitigation measures taken during the combatting of the COVID-19 pandemic.","This paper presents an analysis of risk mitigation measures taken by countries around the world facing the current COVID-19 outbreak. In light of the current pandemic the authors collated and clustered (using harmonised terminology) the risk mitigation measures taken around the globe in the combat to contain, and since March 11 2020, to limit the spread of the SARS-CoV-2 virus known to cause the Coronavirus disease 2019 (COVID-19). This overview gathers lessons learnt, providing an update on the current knowledge for authorities, sectors and first responders on the effectiveness of said measures, and may allow enhanced prevention, preparedness and response for future outbreaks. Various measures such as mobility restrictions, physical distancing, hygienic measures, socio-economic restrictions, communication and international support mechanisms have been clustered and are reviewed in terms of the nature of the actions taken and their qualitative early-perceived impact. At the time of writing, it is still too premature to express the quantitative effectiveness of each risk mitigation cluster, but it seems that the best mitigation results are reported when applying a combination of voluntary and enforceable measures.","Saf Sci","Bruinen de Bruin, Yuri","Lequarre, Anne-Sophie","McCourt, Josephine","Clevestig, Peter","Pigazzani, Filippo","Zare Jeddi, Maryam","Colosio, Claudio","Goulart, Margarida","32296266"],"abstract":["This paper presents an analysis of risk mitigation measures taken by countries around the world facing the current COVID-19 outbreak. In light of the current pandemic the authors collated and clustered (using harmonised terminology) the risk mitigation measures taken around the globe in the combat to contain, and since March 11 2020, to limit the spread of the SARS-CoV-2 virus known to cause the Coronavirus disease 2019 (COVID-19). This overview gathers lessons learnt, providing an update on the current knowledge for authorities, sectors and first responders on the effectiveness of said measures, and may allow enhanced prevention, preparedness and response for future outbreaks. Various measures such as mobility restrictions, physical distancing, hygienic measures, socio-economic restrictions, communication and international support mechanisms have been clustered and are reviewed in terms of the nature of the actions taken and their qualitative early-perceived impact. At the time of writing, it is still too premature to express the quantitative effectiveness of each risk mitigation cluster, but it seems that the best mitigation results are reported when applying a combination of voluntary and enforceable measures."],"journal":"Saf Sci","authors":["Bruinen de Bruin, Yuri","Lequarre, Anne-Sophie","McCourt, Josephine","Clevestig, Peter","Pigazzani, Filippo","Zare Jeddi, Maryam","Colosio, Claudio","Goulart, Margarida"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32296266","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.ssci.2020.104773","keywords":["COVID-19","Corona virus","SARS-CoV-2","mitigation impact","public health","risk mitigation measures"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664266651174961152,"score":224.07065},{"pmid":32241325,"title":"How is COVID-19 affecting South Korea? What is our current strategy?","text":["How is COVID-19 affecting South Korea? What is our current strategy?","The outbreak of coronavirus disease 2019 (COVID-19) caused by the virus SARS-CoV-2 is expanding globally. South Korea is one of the countries most affected by COVID-19 from the very early stages of this pandemic. Explosive outbreaks occurred across South Korea in the first two months, and efforts to control this new virus have involved everyone across the country. To curb the transmission of the virus, health care professionals, committees, and governments have combined many approaches, such as extensive COVID-19 screening, effective patient triage, the transparent provision of information, and the use of information technology. This experience could provide some valuable ideas and lessons to others who are fighting against COVID-19.","Disaster Med Public Health Prep","Her, Minyoung","32241325"],"abstract":["The outbreak of coronavirus disease 2019 (COVID-19) caused by the virus SARS-CoV-2 is expanding globally. South Korea is one of the countries most affected by COVID-19 from the very early stages of this pandemic. Explosive outbreaks occurred across South Korea in the first two months, and efforts to control this new virus have involved everyone across the country. To curb the transmission of the virus, health care professionals, committees, and governments have combined many approaches, such as extensive COVID-19 screening, effective patient triage, the transparent provision of information, and the use of information technology. This experience could provide some valuable ideas and lessons to others who are fighting against COVID-19."],"journal":"Disaster Med Public Health Prep","authors":["Her, Minyoung"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32241325","week":"202014|Mar 30 - Apr 05","doi":"10.1017/dmp.2020.69","keywords":["COVID-19","Outbreak","South Korea"],"source":"PubMed","locations":["South Korea"],"countries":["Korea, Republic of"],"countries_codes":["KOR|Korea, Republic of"],"topics":["Prevention"],"weight":1,"_version_":1663352135713030144,"score":215.63802},{"pmid":32049687,"title":"Overview of The 2019 Novel Coronavirus (2019-nCoV): The Pathogen of Severe Specific Contagious Pneumonia (SSCP).","text":["Overview of The 2019 Novel Coronavirus (2019-nCoV): The Pathogen of Severe Specific Contagious Pneumonia (SSCP).","In late December 2019 a previous unidentified coronavirus, currently named as the 2019 novel coronavirus (2019-nCoV), emerged from Wuhan, China and resulted in a formidable outbreak in many cities in China and expanding globally, including Thailand, Republic of Korea, Japan, USA, Philippines, Viet Nam, and our country (as of 2/6/2020 at least 25 countries). The disease is officially named as the Severe Specific Contagious Pneumonia (SSCP) in 1/15/2019 and is a notifiable communicable disease of the 5 category by the Taiwan CDC, the Ministry of Health. SSCP is a potential zoonotic disease with low to moderate (estimated 2-5%) mortality rate. Person-to-person transmission may occur through droplet or contact transmission and jeopardized first-line healthcare workers if lack of stringent infection control or no proper personal protective equipment available. Currently, there is no definite treatment for SSCP although some drugs are under investigation. To promptly identify patients and prevent further spreading, physicians should be aware of travel or contact history for patients with compatible symptoms.","J Chin Med Assoc","Wu, Yi-Chi","Chen, Ching-Sung","Chan, Yu-Jiun","32049687"],"abstract":["In late December 2019 a previous unidentified coronavirus, currently named as the 2019 novel coronavirus (2019-nCoV), emerged from Wuhan, China and resulted in a formidable outbreak in many cities in China and expanding globally, including Thailand, Republic of Korea, Japan, USA, Philippines, Viet Nam, and our country (as of 2/6/2020 at least 25 countries). The disease is officially named as the Severe Specific Contagious Pneumonia (SSCP) in 1/15/2019 and is a notifiable communicable disease of the 5 category by the Taiwan CDC, the Ministry of Health. SSCP is a potential zoonotic disease with low to moderate (estimated 2-5%) mortality rate. Person-to-person transmission may occur through droplet or contact transmission and jeopardized first-line healthcare workers if lack of stringent infection control or no proper personal protective equipment available. Currently, there is no definite treatment for SSCP although some drugs are under investigation. To promptly identify patients and prevent further spreading, physicians should be aware of travel or contact history for patients with compatible symptoms."],"journal":"J Chin Med Assoc","authors":["Wu, Yi-Chi","Chen, Ching-Sung","Chan, Yu-Jiun"],"date":"2020-02-13T11:00:00Z","year":2020,"_id":"32049687","week":"20207|Feb 10 - Feb 16","doi":"10.1097/JCMA.0000000000000270","source":"PubMed","locations":["South Korea","Wuhan","China","Thailand","USA","Japan","Philippines","Viet Nam"],"countries":["United States","Japan","Thailand","Korea, Republic of","Philippines","China","Viet Nam"],"countries_codes":["USA|United States","JPN|Japan","THA|Thailand","KOR|Korea, Republic of","PHL|Philippines","CHN|China","VNM|Viet Nam"],"topics":["Diagnosis","Prevention"],"weight":1,"_version_":1663352134682279936,"score":212.90681},{"pmid":32134861,"title":"The outbreak of COVID-19: An overview.","text":["The outbreak of COVID-19: An overview.","In late December 2019, a previous unidentified coronavirus, currently named as the 2019 novel coronavirus#, emerged from Wuhan, China, and resulted in a formidable outbreak in many cities in China and expanded globally, including Thailand, Republic of Korea, Japan, United States, Philippines, Viet Nam, and our country (as of 2/6/2020 at least 25 countries). The disease is officially named as Coronavirus Disease-2019 (COVID-19, by WHO on February 11, 2020). It is also named as Severe Pneumonia with Novel Pathogens on January 15, 2019 by the Taiwan CDC, the Ministry of Health and is a notifiable communicable disease of the fifth category. COVID-19 is a potential zoonotic disease with low to moderate (estimated 2%-5%) mortality rate. Person-to-person transmission may occur through droplet or contact transmission and if there is a lack of stringent infection control or if no proper personal protective equipment available, it may jeopardize the first-line healthcare workers. Currently, there is no definite treatment for COVID-19 although some drugs are under investigation. To promptly identify patients and prevent further spreading, physicians should be aware of the travel or contact history of the patient with compatible symptoms.","J Chin Med Assoc","Wu, Yi-Chi","Chen, Ching-Sung","Chan, Yu-Jiun","32134861"],"abstract":["In late December 2019, a previous unidentified coronavirus, currently named as the 2019 novel coronavirus#, emerged from Wuhan, China, and resulted in a formidable outbreak in many cities in China and expanded globally, including Thailand, Republic of Korea, Japan, United States, Philippines, Viet Nam, and our country (as of 2/6/2020 at least 25 countries). The disease is officially named as Coronavirus Disease-2019 (COVID-19, by WHO on February 11, 2020). It is also named as Severe Pneumonia with Novel Pathogens on January 15, 2019 by the Taiwan CDC, the Ministry of Health and is a notifiable communicable disease of the fifth category. COVID-19 is a potential zoonotic disease with low to moderate (estimated 2%-5%) mortality rate. Person-to-person transmission may occur through droplet or contact transmission and if there is a lack of stringent infection control or if no proper personal protective equipment available, it may jeopardize the first-line healthcare workers. Currently, there is no definite treatment for COVID-19 although some drugs are under investigation. To promptly identify patients and prevent further spreading, physicians should be aware of the travel or contact history of the patient with compatible symptoms."],"journal":"J Chin Med Assoc","authors":["Wu, Yi-Chi","Chen, Ching-Sung","Chan, Yu-Jiun"],"date":"2020-03-06T11:00:00Z","year":2020,"_id":"32134861","week":"202010|Mar 02 - Mar 08","doi":"10.1097/JCMA.0000000000000270","source":"PubMed","locations":["South Korea","Philippines","Wuhan","China","Thailand","Japan","United States","Viet Nam"],"countries":["United States","Japan","Thailand","Korea, Republic of","Philippines","China","Viet Nam"],"countries_codes":["USA|United States","JPN|Japan","THA|Thailand","KOR|Korea, Republic of","PHL|Philippines","CHN|China","VNM|Viet Nam"],"topics":["Diagnosis","Prevention"],"weight":1,"_version_":1663352134210420736,"score":211.98933}]}